# Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

> **NCT06399107** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 85 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle-Cell Disease With Crisis

## Interventions

- **GENETIC:** Drug Product is administered by IV infusion following myeloablative conditioning with busulfan

## Key facts

- **NCT ID:** NCT06399107
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-12-28
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06399107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06399107, "Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06399107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*